Efficacy of T2 in Active Crohn’s Disease: A Prospective Study Report

详细信息    查看全文

• 作者：Jianan Ren ; Qingsong Tao ; Xinbo Wang ; Zhiming Wang and Jieshou Li
• 关键词：Tripterygium wilfordii ; Crohn’s disease ; Crohn’s disease activity index ; Crohn’s Disease Endoscopic Index of Severity ; Tumor necrosis factor ; α ; Interleukin ; 1β
• 刊名：Digestive Diseases and Sciences
• 出版年：2007
• 出版时间：August, 2007
• 年：2007
• 卷：52
• 期：8
• 页码：1790-1797
• 全文大小：368 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Hepatology
  Oncology
  Transplant Surgery
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-2568

文摘

To date few therapies have been shown to reliably prevent the evolution of Crohn’s disease (CD). The traditional Chinese medicine, Tripterygium wilfordii Hook F (TWHF), has both immunomodulatory and anti-inflammatory activities. Our aim was to investigate the potential efficacy of T2, the major constituent of extracts of TWHF, in inducing remission of active CD. Twenty adult patients with active CD were enrolled to be treated with T2 pills (60 mg daily) for 12 weeks. Plasma levels of C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and interleukin (IL)-1β were measured at entry and every 2 weeks thereafter until week 12. At each visit the CD Activity Index (CDAI) was calculated. The CD Endoscopic Index of Severity was measured at entry and week 12. Sixteen patients completed the study. A significant decrease in serum levels of CRP, TNF-α, and IL-1β occurred rapidly after commencement of treatment. CDAI scores showed a rapid decline during the first 8 weeks and reached their lowest at week 10. Endoscopic improvements were observed at week 12. In conclusion, T2 appears to be effective for the treatment of mildly or moderately active CD. Further controlled studies are warranted for this promising drug.